Mantedanib Capsule 150mg contains Nintedanib 150mg, a potent tyrosine kinase inhibitor indicated for the treatment of various fibrotic and oncologic conditions. Nintedanib acts by selectively inhibiting multiple receptor tyrosine kinases involved in the pathogenesis of diseases characterized by abnormal cell proliferation and fibrosis, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR). This mechanism results in the attenuation of pathological angiogenesis and fibrogenesis. Mantedanib is primarily prescribed for the management of idiopathic pulmonary fibrosis (IPF), where it helps to slow disease progression by reducing fibroblast proliferation and collagen deposition in lung tissue. Additionally, it is utilized in the treatment of certain cancers, such as non-small cell lung cancer (NSCLC), often in combination with other chemotherapeutic agents. The recommended dosage is one 150mg capsule taken orally twice daily with food to enhance absorption and minimize gastrointestinal adverse effects. Common side effects include diarrhea, nausea, vomiting, and elevated liver enzymes, necessitating regular monitoring of hepatic function during therapy. Caution is advised in patients with hepatic impairment or bleeding disorders. Mantedanib should be prescribed and monitored by healthcare professionals experienced in managing fibrotic lung diseases and malignancies.